DARA Biosciences Inc (NASDAQ:DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that Soltamox has been added to the Federal Supply Schedule for purchase by all government agencies. DARA Biosciences Inc (NASDAQ:DARA)stock performance was -4.12% in last session and finished the day at $ 1.63. Traded volume was 169,677 shares in the last session and the average volume of the stock remained 401,567 shares. The beta of the stock remained 0.67. DARA Biosciences Inc (NASDAQ:DARA) insider ownership is 0.90%.
RXi Pharmaceuticals Corp (NASDAQ:RXII)’s shares opened at 3.32 on Monday. RXi Pharmaceuticals Corp has a 52-week low of $2.55 and a 52-week high of $6.84. The stock’s 50-day moving average is $4.10 and its 200-day moving average is $3.98. The company’s market cap is $44.4 million.RXi Pharmaceuticals Corp (NASDAQ:RXII) dropped -8.18% to $ 3.03 yesterday on volume of 290,183 shares. The intra-day range of the stock was $ 2.87 – 3.35. RXi Pharmaceuticals Corp (NASDAQ:RXII) has a market capitalization of $ 40.52 million.
Spherix Inc (NASDAQ:SPEX) an intellectual property development company committed to the fostering and monetization of intellectual property, commenced litigation against Juniper Networks, Inc. (JNPR), in the United States District Court for the District of Delaware, alleging that the Sunnyvale, California based company infringes five patents owned by Spherix. Spherix Inc (NASDAQ:SPEX)’s stock on May 7, 2014 reported a decrease of -9.46% to the closing price of $ 1.34. Its fifty two weeks range is $ 1.30 – 27.86. The total market capitalization recorded $ 10.51 million. The overall volume in the last trading session was 40.45 million shares. In its share capital, Spherix Inc(NASDAQ:SPEX) has 7.86 million outstanding shares.
Biodel Inc (NASDAQ:BIOD) announced another development in its Glucagon Emergency Management (GEM) development program with the signing of a long-term manufacturing agreement with Cangene bioPharma Inc. doing business as Emergent BioSolutions (“Emergent”). Under the agreement, Emergent will fill and finish commercial quantities of the GEM device. Financial terms of the agreement have not been disclosed. On Friday, shares of Biodel Inc (NASDAQ:BIOD) dropped -5.33% to close the day at $ 2.13. Company monthly performance is recorded as -18.39%. Biodel Inc (NASDAQ:BIOD)quarterly revenue growth is -18.08%.